HealthPolitics

STAT+: At ESMO, AstraZeneca’s cancer pursuits get a showcase

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 25/10/2026, 17:06:24 UTC.

Briefings

AstraZeneca's cancer research is advancing at the European Society for Medical Oncology congress in Madrid, where four of its 12 presentations in presidential sessions featured AZ medicines. Susan Galbraith, head of AZ's cancer R&D, noted the breadth of the portfolio and the quality of data presented. The event highlights new combinations of approved drugs and potential next-generation targeted chemotherapy. The article was published on October 25, 2026, and the evidence is untrusted data.

Key points

• Four of the 12 presentations in the presidential sessions at the European Society for Medical Oncology congress featured AstraZeneca medicines.
• Susan Galbraith, head of AstraZeneca's cancer R&D, stated that the conference demonstrates the breadth of the company's portfolio and the quality of data presented.

Context

The article describes AstraZeneca's cancer work as 'steamrolling ahead' at the ESMO congress in Madrid, Spain, highlighting new drug combinations and potential targeted chemotherapy. The evidence is untrusted data, and no additional background context or source link is supplied.

Limitations

The evidence is limited to a single article from October 25, 2026, covering only four of twelve presentations. It does not provide dates for the new targeted chemotherapy, specific numbers for presentation slots, or details on the company's overall market position or future plans beyond the conference.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 25/10/2026, 17:13:32 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeifhnpqyzklamgc42xw5vr6rccze34dxwxy7d6hfwdoevaoi6vfyxm